GTEC Competitors

Abacus Health Products (OTCMKTS:ABAHF) and GTEC (OTCMKTS:GGTTF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Abacus Health Products and GTEC, as reported by MarketBeat.

Valuation & Earnings

This table compares Abacus Health Products and GTEC's gross revenue, earnings per share and valuation.

Profitability

This table compares Abacus Health Products and GTEC's net margins, return on equity and return on assets.

Acreage (OTCMKTS:ACRGF) and GTEC (OTCMKTS:GGTTF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Acreage and GTEC, as reported by MarketBeat.

Acreage currently has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given Acreage's higher possible upside, analysts plainly believe Acreage is more favorable than GTEC.

Valuation & Earnings

This table compares Acreage and GTEC's gross revenue, earnings per share and valuation.

Profitability

This table compares Acreage and GTEC's net margins, return on equity and return on assets.

Summary

Acreage beats GTEC on 2 of the 2 factors compared between the two stocks.

Applied Biosciences (OTCMKTS:APPB) and GTEC (OTCMKTS:GGTTF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Applied Biosciences and GTEC, as reported by MarketBeat.

Valuation & Earnings

This table compares Applied Biosciences and GTEC's gross revenue, earnings per share and valuation.

Profitability

This table compares Applied Biosciences and GTEC's net margins, return on equity and return on assets.

Ayr Strategies (OTCMKTS:AYRSF) and GTEC (OTCMKTS:GGTTF) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Ayr Strategies and GTEC's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ayr Strategies and GTEC, as reported by MarketBeat.

Ayr Strategies currently has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given Ayr Strategies' higher possible upside, analysts plainly believe Ayr Strategies is more favorable than GTEC.

Valuation & Earnings

This table compares Ayr Strategies and GTEC's gross revenue, earnings per share and valuation.

Summary

Ayr Strategies beats GTEC on 2 of the 2 factors compared between the two stocks.

Can B (NASDAQ:CANB) and GTEC (OTCMKTS:GGTTF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares Can B and GTEC's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Can B and GTEC, as reported by MarketBeat.com.

Valuation and Earnings

This table compares Can B and GTEC's gross revenue, earnings per share and valuation.

Cansortium (OTCMKTS:CNTMF) and GTEC (OTCMKTS:GGTTF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Profitability

This table compares Cansortium and GTEC's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cansortium and GTEC, as reported by MarketBeat.com.

Cansortium presently has a consensus target price of $1.20, indicating a potential upside of 35.90%. Given Cansortium's higher possible upside, equities analysts clearly believe Cansortium is more favorable than GTEC.

Valuation and Earnings

This table compares Cansortium and GTEC's gross revenue, earnings per share and valuation.

Summary

Cansortium beats GTEC on 2 of the 2 factors compared between the two stocks.